PMID- 38058541
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231208
IS  - 2296-9195 (Print)
IS  - 2296-9160 (Electronic)
IS  - 2296-9160 (Linking)
VI  - 9
IP  - 6
DP  - 2023 Dec
TI  - Resorcinol 10% as a Promising Therapeutic Option for Mild Hidradenitis 
      Suppurativa: A Prospective, Randomized, Open Study.
PG  - 438-443
LID - 10.1159/000531926 [doi]
AB  - INTRODUCTION: Treatment of hidradenitis suppurativa (HS) is challenging, and in 
      Hurley stage I, it is based on topical measures. Our aim was to compare the 
      efficacy and safety of topical resorcinol 10% with topical clindamycin 1% and no 
      therapy, in Hurley stage I HS. METHODS: In this open, prospective, randomized 
      trial, we studied 60 Hurley stage I patients with IHS4 </=10. Group A was treated 
      with topical resorcinol 10%; group B with clindamycin lotion 1%; and group C 
      received no treatment. Patients were evaluated by total lesion count, the 
      International Hidradenitis Suppurativa Severity Score System (IHS4) and the 
      Dermatology Life Quality Index (DLQI) at baseline, 12 and 24 weeks. Self-reported 
      number of flares and adverse events (AEs) were recorded. RESULTS: A significant 
      reduction in the mean total lesion count and DLQI scores were observed in group 
      A, compared to group B at week 12 (p = 0.036, p < 0.001, respectively), and in 
      the mean total lesion count, IHS4, and DLQI scores at week 24 (p = 0.034, p = 
      0.017, p < 0.001, respectively). Resorcinol 10% was well-tolerated with only mild 
      AEs. CONCLUSION: Resorcinol 10% may represent a useful alternative for the 
      long-term treatment of mild HS, which is superior to topical clindamycin and has 
      a favorable safety profile.
CI  - (c) 2023 S. Karger AG, Basel.
FAU - Katoulis, Alexander
AU  - Katoulis A
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
FAU - Efthymiou, Ourania
AU  - Efthymiou O
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
FAU - Liakou, Aikaterini
AU  - Liakou A
AD  - 1st Department of Dermatology-Venereology, National and Kapodistrian University 
      of Athens, Medical School, "Andreas Sygros" Hospital for Cutaneous and Venereal 
      Diseases, Athens, Greece.
FAU - Pappa, Georgia
AU  - Pappa G
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
FAU - Kanelleas, Antonios
AU  - Kanelleas A
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
FAU - Koumaki, Dimitra
AU  - Koumaki D
AD  - Dermatology Department, University Hospital of Heraklion, Heraklion, Greece.
FAU - Bozi, Evangelia
AU  - Bozi E
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
FAU - Sgouros, Dimitrios
AU  - Sgouros D
AD  - 2nd Department of Dermatology and Venereology, National and Kapodistrian 
      University of Athens, Medical School, "Attikon" General University Hospital, 
      Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20230816
PL  - Switzerland
TA  - Skin Appendage Disord
JT  - Skin appendage disorders
JID - 101670617
PMC - PMC10697770
OTO - NOTNLM
OT  - Clindamycin
OT  - Hidradenitis suppurativa
OT  - Resorcinol
OT  - Topical therapy
OT  - Treatment
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/12/07 06:42
MHDA- 2023/12/07 06:43
PMCR- 2024/12/01
CRDT- 2023/12/07 04:06
PHST- 2023/03/03 00:00 [received]
PHST- 2023/06/16 00:00 [accepted]
PHST- 2024/12/01 00:00 [pmc-release]
PHST- 2023/12/07 06:43 [medline]
PHST- 2023/12/07 06:42 [pubmed]
PHST- 2023/12/07 04:06 [entrez]
AID - 531926 [pii]
AID - 10.1159/000531926 [doi]
PST - ppublish
SO  - Skin Appendage Disord. 2023 Dec;9(6):438-443. doi: 10.1159/000531926. Epub 2023 
      Aug 16.